BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25637587)

  • 1. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
    Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
    Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
    Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.
    Abedi GR; Mutuc JD; Lawler J; Leroy ZC; Hudson JM; Blog DS; Schulte CR; Rausch-Phung E; Ogbuanu IU; Gallagher K; Kutty PK
    Vaccine; 2012 Nov; 30(49):7052-8. PubMed ID: 23041123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
    Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
    Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
    Moro PL; Leung J; Marquez P; Kim Y; Wei S; Su JR; Marin M
    J Infect Dis; 2022 Oct; 226(Suppl 4):S431-S440. PubMed ID: 36265846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.
    Moro PL; Zheteyeva Y; Barash F; Lewis P; Cano M
    Vaccine; 2018 Jan; 36(1):50-54. PubMed ID: 29174107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
    Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy.
    Cocchio S; Zanoni G; Opri R; Russo F; Baldo V;
    Hum Vaccin Immunother; 2016 Mar; 12(3):651-4. PubMed ID: 26528829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
    Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.